Pacific Biosciences Of Stock Today
| PACB Stock | USD 1.85 0.37 25.00% |
PerformanceModest
| Odds Of DistressAbout Average
|
Pacific Biosciences is trading at 1.85 as of the 16th of February 2025, a 25.00% up since the beginning of the trading day. The stock's open price was 1.48. Pacific Biosciences has 50 percent odds of going through some form of financial distress in the next two years and did not have a very good performance for investor during the last 90 trading days. The performance scores are derived for the period starting the 17th of January 2025 and ending today, the 16th of February 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 27th of October 2010 | Category Healthcare | Classification Health Care |
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California. Pacific Biosciences operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. The company has 294.32 M outstanding shares of which 60.4 M shares are at this time shorted by private and institutional investors with about 5.81 trading days to cover. More on Pacific Biosciences of
Moving together with Pacific Stock
Moving against Pacific Stock
Pacific Stock Highlights
| CEO, President | Christian MBA | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Ideas | (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Life Sciences Tools & Services, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Aggressive Defence, Measuring and Control Equipment, Health Care, Life Sciences Tools & Services, Medical Devices, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsPacific Biosciences can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Pacific Biosciences' financial leverage. It provides some insight into what part of Pacific Biosciences' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Pacific Biosciences of (PACB) is traded on NASDAQ Exchange in USA. It is located in 1305 O?Brien Drive, Menlo Park, CA, United States, 94025 and employs 796 people. Pacific Biosciences is listed under Life Sciences Tools & Services category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 544.48 M. Pacific Biosciences conducts business under Life Sciences Tools & Services sector and is part of Health Care industry. The entity has 294.32 M outstanding shares of which 60.4 M shares are at this time shorted by private and institutional investors with about 5.81 trading days to cover.
Pacific Biosciences of currently holds about 834.34 M in cash with (259.17 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.69, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Pacific Biosciences Probability Of Bankruptcy
Ownership AllocationPacific Biosciences owns a total of 294.32 Million outstanding shares. The majority of Pacific Biosciences of outstanding shares are owned by third-party entities. These institutional holders are usually referred to as non-private investors looking to secure positions in Pacific Biosciences to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Pacific Biosciences. Please pay attention to any change in the institutional holdings of Pacific Biosciences as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Pacific Ownership Details
Pacific Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Bank Of New York Mellon Corp | 2024-12-31 | 5.2 M | |
| Goldman Sachs Group Inc | 2024-09-30 | 4.2 M | |
| Morgan Stanley - Brokerage Accounts | 2024-09-30 | 3.9 M | |
| Capital World Investors | 2024-09-30 | 3.4 M | |
| Jane Street Group Llc | 2024-09-30 | 2.7 M | |
| Northern Trust Corp | 2024-09-30 | 2.4 M | |
| Bank Of America Corp | 2.4 M | ||
| Charles Schwab Investment Management Inc | 2024-12-31 | 2.2 M | |
| Marshall Wace Asset Management Ltd | 2024-09-30 | 2.1 M | |
| Ark Investment Management Llc | 2024-12-31 | 36 M | |
| Madrone Advisors Llc | 2024-09-30 | 23.4 M |
Pacific Biosciences Historical Income Statement
Pacific Stock Against Markets
Pacific Biosciences Corporate Management
| Brett JD | General Secretary | Profile | |
| Stephen Turner | CoFounder CTO | Profile | |
| Susan Kim | Chief Officer | Profile | |
| Jeff Eidel | Chief Officer | Profile | |
| Denis Zaccarin | Senior Development | Profile | |
| Michele CPA | VP Officer | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pacific Biosciences of. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pacific Biosciences. If investors know Pacific will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pacific Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.58) | Revenue Per Share | Quarterly Revenue Growth (0.33) | Return On Assets | Return On Equity |
The market value of Pacific Biosciences is measured differently than its book value, which is the value of Pacific that is recorded on the company's balance sheet. Investors also form their own opinion of Pacific Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Pacific Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pacific Biosciences' market value can be influenced by many factors that don't directly affect Pacific Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pacific Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Pacific Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pacific Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.